Kornimate/medical-research-clean huggingface dataset:
developing a chatbot to promote hiv testing

Conditions: HIV Infections

Summary: in this study, the feasibility of a chatbot in promoting hiv testing in a pilot rct with 80 men who have sex with men in kuala lumpur, malaysia will be studied. participants will be randomized to chatbot or treatment as usual (tau) groups. participants in the intervention group will receive automated personalized messages containing hiv testing-related information, motivation and skills.

after informed consent, participants will be randomly assigned to chatbot or tau groups using stratified randomization by age. participants in tau will receive attention-matched educational materials manually sent by the research assistant. participants in the intervention group will receive an automated personalized question message (root-node message) from the chabot. in each round of the interactive communication, the chatbot will provide automated personalized messages containing hiv testing-related information, motivation and skills based on participants' answers and will continuously update over time. participants will be observed over 180 days with responses and interactions stored on a hipaa-compliant and protected cloud. an independent assessment of recent testing and reasons why will be sent by link to both tau and intervention groups using a link to a qualtrics survey housed on redcap at baseline and after 90 and 180 days. after 180 days, the ra will send an additional redcap survey to intervention participants to assess the feasibility of the chabot to measure 4 key elements: acceptability, practicality, demand, and adaptation.

Eligibility criteria:
inclusion criteria: * cis-gender male * 18+ years; * had condomless sex with men in the past 6 months * has a smartphone * speaks bahasa malay or english. exclusion criteria: * not able to read malay or english

Keywords: hiv testing prep hiv care chatbot msm
expectant management of ectopic pregnancy

Conditions: Ectopic Pregnancy

Summary: the aim of this study is to assess the efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy and identification of different factors that can be used to predict its success.


Eligibility criteria:
inclusion criteria: - all women who underwent expectant management as the first line of management offered after optimal counseling during the period from january 1, 2016 to december 31, 2020. 1. hemodynamically stable with confirmed diagnosis of ectopic pregnancy on ultrasound scan. 2. no significant pelvic pain. 3. no hemoperitoneum. 4. no fetal heart in the ectopic pregnancy. 5. hcg level \<5000 iu/l. 6. expectant management was the first line of management offered to the patient after optimal counseling. exclusion criteria: 1. all women with non tubal ectopic pregnancy 2. all women with tubal ectopic pregnancy that recieved medical or surgical treatment as 1st line treatment
effects of nitric oxide for inhalation in myocardial infarction size

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to determine the effects of nitric oxide for inhalation on myocardial infarction size.

the primary objective of the trial is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (mi) size as a fraction of left ventricular size at 48-72 hours in patients presenting with an st segment elevation mi who undergo successful percutaneous coronary intervention.

Eligibility criteria:
inclusion criteria: 1. acute myocardial infarction (defined as an episode of chest pain or related symptom lasting greater than 2 hours but less than 12 hours and electrocardiographic evidence of st elevation (measured as 0.08 seconds after the j point; sum greater or equal to 0.6 mv in leads i, ii, iii, avl, avf, v1-v6). 2. no evidence of congestive heart failure (no s3 or evidence of pulmonary edema) and normal oxygen saturation on ≤ 2l oxygen by nc. 3. all patients must undergo successful percutaneous coronary intervention for timi 0 or 1 coronary flow with resulting timi 2 or 3 (residual stenosis less than 30% if stented and less than 50% if opened by balloon angioplasty). 4. age \> 18 years. 5. signed ec approved informed consent. exclusion criteria: 1. prior myocardial infarction (as determined by patient history and/or ecg), cardiac surgery, or severe pericardial, congenital, cardiomyopathic or valvular heart disease. 2. requirement for urgent cardiac surgery. 3. previous cabg or pci. 4. left bundle branch block. 5. unable to tolerate magnetic resonance imaging (including disallowed metallic implants or bmi \> 35) or unable to tolerate gadolinium contrast media, including patients with calculated creatinine clearance less than 60 ml/min/1.73 m2 bsa. 6. active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation or hemorrhagic stroke within the 6 weeks prior to presentation. 7. known or suspected aortic dissection. 8. prior history of pulmonary disease requiring chronic oxygen therapy. 9. pregnancy, lactating and woman of childbearing potential. 10. use of investigational drugs or device within the 30 days prior to enrollment to the study. investigational uses of approved therapies will be allowed. 11. medical problem likely to preclude completion of the study.

Keywords: st elevation mi stemi
phase iii randomized, double-blind study of potassium phosphate vs potassium citrate for absorptive hypercalciuria

Conditions: Hypercalciuria; Kidney Calculi

Summary: objectives: i. evaluate the ability of a slow-releasing formulation of neutral potassium phosphate to correct hypercalciuria and prevent recurrent stone formation in patients with absorptive hypercalciuria. ii. evaluate the safety of this treatment. iii. compare the efficacy of potassium phosphate to that of potassium citrate.

protocol outline: this is a randomized, double-blind study. patients are stratified by participating institution. patients receive potassium phosphate or potassium citrate tablets twice a day for 3 years.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- absorptive hypercalciuria intestinal hyperabsorption of calcium, i.e.: exaggerated calciuric response to oral calcium load or fractional calcium-47 absorption greater than 0.61 calciuria greater than 200 mg/day on random and calcium-restricted diet normal or high fasting urinary calcium normal serum calcium normal serum parathyroid hormone no primary hyperparathyroidism at least 1 calcium oxalate stone within the past 3 years no struvite or carbonate apatite stones no noncalcareous stones no numerous stones making precise quantitation difficult no renal tubular acidosis --prior/concurrent therapy-- no concurrent drug therapy for nephrolithiasis --patient characteristics-- creatinine clearance at least 0.7 ml/min per kilogram no hyperkalemia no hyperphosphatemia no urinary tract infection other: no predisposition to hyperkalemia, including concurrent use of the following drugs: potassium-sparing diuretics angiotensin-converting enzyme inhibitors nonsteroidal anti-inflammatory drugs no active peptic ulcer disease no chronic diarrhea

Keywords: hypercalciuria nephrolithiasis rare disease renal and genitourinary disorders
oral dietary fucoxanthin rich supplement for liver health

Conditions: Non Alcoholic Fatty Liver

Summary: blind, placebo-controlled study testing the hypothesis that oral dietary supplement rich with fucoxanthin will decrease biochemical clinical markers related to liver health.

six month supplementation

Eligibility criteria:
inclusion criteria: * healthy adults \> 18 years * willing to sign an informed consent to participate in the study. * non-smokers. * blood results above the normal range in hepatic function testing consisting of panels containing alt, ast, alp, total bilirubin and albumin and abdominal ultrasonography. * over-weight (bmi ≥ 27 kg/m2) who fulfill the criteria of the national cholesterol education program (ncep) metabolic syndrome. exclusion criteria: * pregnancy. * presence of gastrointestinal or mental disorders, diabetes mellitus, alcohol abuse, weight-loss treatment, bariatric surgery, unusual diets (vegetarian, vegan), daily usage of antioxidants dietary supplements at the last 4 months (for subjects in stage 2 of the study). * serious medical conditions.

Keywords: fucoxanthin microalgae non alcoholic fatty liver
torsion optimization to reduce symptoms and improve outcomes in non-responders

Conditions: Heart Failure, Congestive

Summary: approximately 40% of resynchronization therapy recipients do not appear to clearly benefit. these patients are termed 'non-responders'. this study will assess whether a heart ultrasound (echo) technique called 'torsion imaging' can be used to increase the likelihood of benefit from resynchronization therapy.

background: despite advances in pharmacotherapy, patients with heart failure (hf) are at high risk for death and hospitalization. over 25% of patients with systolic hf have dyssynchronous ventricular contraction that impairs left ventricular (lv) function and results in hf progression. cardiac resynchronization therapy (crt) is designed to synchronize ventricular mechanical activity, improving cardiac output and reducing hf symptoms. as shown in our pilot data, at least 40% of patients do not respond to crt despite pre-screening for the presence of longitudinal (long axis) mechanical (velocity) dyssynchrony and targeting lv lead placement to the latest site of latest velocity. methods to improve the rates of response to crt are required. torsion imaging guided optimization of crt timing is a promising approach and will be tested in this study. primary hypothesis: optimization of inter-ventricular (vv) timing, guided by torsion imaging, will increase functional capacity and reduce lv end systolic volume \[esv\] in crt in patients who have not responded after ≥ 6 months. crt response will be defined by a ≥ 1 functional class improvement and either a ≥ 10% reduction in lv esv or a ≥ 5% increase in ef at follow-up versus baseline. secondary aims: to compare the following in torsion-guided vs usual care patients: a) echo parameters (intra-lv and vv dyssynchrony and torsion, and mitral regurgitation), b) n-terminal bnp levels, and c) generic / disease-specific quality of life. methods: randomized study of patients who have not responded to crt after ≥ 6 months.

Eligibility criteria:
inclusion criteria: * non-response to crt as indicated, * stable doses of ace i / arb and beta-blocker for ≥ 2 months, \& * controlled heart rate if in atrial fibrillation. exclusion criteria: * inadequate images to assess torsion * no significant augmentation in torsion with optimization * unable or unwilling to provide informed consent, * medical condition other than hf likely to cause death within 6 months, * cardiac transplant planned, * myocardial infarction or revascularization since crt implant.

Keywords: crt, resynchronization,
validity study of glutamine to improve cardiac function in cardiac surgery

Conditions: Rheumatic Heart Disease; Coronary Heart Disease

Summary: in view of the lack of large-scale clinical study and potent evidence-based medicine, the investigators designed a randomized, double-blind, placebo-controlled study to ascertain whether preoperative intravenous administration with glutamine can improve the postoperative cardiac function and prognosis of adult patients undergoing cardiac surgery. the investigators want to detect the levels of myocardial protein o-glcnac modification and hsp70 expression, changes in sensitive indicators of myocardial injury, systemic inflammatory reaction and oxidative stress levels, and to examine the correlation between these changes and clinical manifestations. the ultimate goal of the study is to explore a new way for clinical myocardial protection.

cardiosurgery is mostly done under cardiopulmonary bypass. however, the cardiopulmonary bypass and the later recovery of spontaneous circulation, a cardiac ischemia / reperfusion process, may cause myocardial damage and affect cardiac function as well as prognosis. glutamine, an amino acid abundant in the human body, plays an important role in the regulation of metabolism and immune cells and the protection of organs. relative lack of glutamine is reported during stress or serious illness. animal studies have confirmed that pretreatment with glutamine has a protective effect on the heart, liver, kidney and other organs post ischemia / reperfusion injury. it is also established that glutamine exerts myocardial protection mainly by activating hexosamine biosynthetic pathway, increasing intracellular o-glcnac protein modification and expression of heat shock protein 70 (hsp70), starting the protective reaction in the body, improving the function of myocardial cells, and inhibiting the release of inflammatory cytokines and oxidative stress levels. besides, clinical studies have shown that at the perioperative stage glutamine has a protective effect on cardiac function of the patients treated with pump coronary artery bypass surgery. the purpose of this study is to ascertain whether preoperative intravenous administration with glutamine (as compared with control group) can improve the postoperative cardiac function and prognosis of adult patients undergoing cardiac surgery and reduce inflammatory response and oxidative stress levels of the body. the correlation between clinical manifestations and expression of myocardium o-glcnac and hsp70 will also be investigated.

Eligibility criteria:
inclusion criteria: * adult patients with coronary artery disease or rheumatic heart disease accepted cardiosurgery under cardiopulmonary bypass exclusion criteria: * ejection fraction(ef)\<50% * preoperative support with intra-aortic balloon pump(iabp) * hepatosis * renal dysfunction * myocardial infarction attack within 3 months * emergency operation

Keywords: glutamine cardiosurgery cardiopulmonary bypass cardiac function recovery
effectiveness of a team-based follow-up program in general practice among people with chronic conditions

Conditions: Diabetes Type 2; COPD

Summary: the study will develop and evaluate the effectiveness of a team-based follow-up program in general practice (gp) among people with chronic conditions.

the epidemic proportion of lifestyle related non-communicable diseases is a worldwide challenge and public health problem resulting in significant hospitalization rates, mortality and morbidity, and huge personal and societal costs. this project involves research for better public health and health outcomes acknowledging the need for improvements in the health-care services in the prevention of risks and harm and better risk-factor management. we will conduct a randomized control study in four gp practices with ≥3 gps and ≥one nurse among 154 people at risk for developing type 2 diabetes mellitus (t2dm) or manifest disease, and 154 people in the control group. inclusion criteria are diabetes risc calculator (findrisc) ≥ 15 or hba1c ≥6,5 % or specific need for individualized follow up such as body mass index (bmi) ≥ 30. in addition, we will conduct a feasibility study among 30 people with risk for chronic pulmonary disease (copd) or manifest disease. the study has the following two objectives: 1) to evaluate the effectiveness of a team-based follow-up program among people with risk for t2dm or manifest t2dm with the use of guided self-determination (gsd) as an empowerment approach for patients in general practice, 2) to test the feasibility and pilot a team-based follow-up program among people with risk for copd or manifest copd with the use of gsd as an empowerment approach for patients in general practice.

Eligibility criteria:
inclusion criteria: * aged between 20-80 years with findrisc score ≥15 * body mass index ≥ 30 * manifest t2dm (hba1c ≥48 mmol/mol (6,5%)) * positive smoking status (risk for copd) * manifest copd (spirometry value: fev1/fvc \< 0,7). exclusion criteria: * severe somatic disease (cancer, end stage renal disease) * severe psychiatric diagnosis or dementia * patients who do not understand nor speak norwegian.
sleep apnea in patients with mgus and mm

Conditions: Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance

Summary: this study involves patients with plasma cell dyscrasia including monoclonal gammopathy of undetermined significance (mgus) or multiple myeloma (mm), with and without sleep apnea, who are providing bone marrow specimens. specimens will be obtained at the time that patients undergo a standard-of-care procedure in order to minimize discomfort and reduce any risk.

obesity is a risk factor for the development of mm, although the mechanisms that link obesity and mm are unclear. obesity, in turn, is closely associated with obstructive sleep apnea. interestingly, the key risk factors for both sleep apnea and mm are overlapping (age, sex, race and body mass index). during the apnea, or cessation of normal breathing, arterial oxygen saturation falls. this can occur as often as 60 times per hour, resulting in chronic intermittent hypoxia (cih). in preliminary studies, investigators exposed c57bl/6 mice, that are typically resistant to engraftment of malignant plasma cells to cih, followed by injection of malignant 5tgm1 cells. with cih, 5tgm1 cells homed to bone marrow, and engrafted and expanded, resulting in lethal disease. these mice had key features of the myeloma phenotype, including bone damage and gammopathy. investigators explored potential mechanisms by which cih promote mm progression by performing whole bone marrow rnaseq analysis. they found pathways relevant to angiogenesis, cell adhesion, and stromal cell development (including dendritic cells and eosinophils) to be upregulated. this is an exciting and potentially translational finding because these elements are also upregulated in the bone marrow of human myeloma patients. investigators also found upregulation of b cell and plasma cell development and differentiation pathway, and downregulation of b-cell apoptosis pathways. taking these preliminary findings together, the overarching hypothesis is that cih increases oxidative stress, thereby supporting b cell maturation and changing the bone marrow stromal microenvironment to drive the progression to mm.

Eligibility criteria:
patients diagnosed with mgus or mm who will be receiving a bone marrow biopsy as part of their standard of care are eligible to participate in this study
18f-dopa-pet in non-tumoral and tumoral brain lesions

Conditions: Brain Tumor

Summary: background: 3,4-dihydroxy-6-\[18f\]-fluoro-l-phenylalanine (fdopa) positron emission tomography (pet) can identify well low and high grade brain tumors. however, increased fdopa uptake has been reported in non-tumoral brain lesions. the aim was to analyse fdopa-pet in patients with non-tumoral brain lesions and to compare them with patients with (low and high grade) brain tumors. methods: retrospective analyse. patients consecutively recruited with suspected primary brain tumor (based on clinical and mri findings) referred for fdopa-pet at nimes university hospital between june 2015 and june 2019. fdopa-pet parameters (maximum and mean lesion standardized uptake values \[suv\] and ratios comparing lesion with different background uptake suv) and thresholds were analysed in search for those offering optimal discrimination between non-tumoral and tumoral lesions.


Eligibility criteria:
inclusion criteria: * presence of defined tumor (histology was required) or non-tumor (diagnosed by histological or other analyses) diagnosis, * clinical and mri follow-up of \>24 months, * fdopa-pet scan \<2 months before surgery or stereotactic biopsy (when performed)

Keywords: tumor tumoral non-tumoral pseudotumoral 3,4-dihydroxy-6-[18f]-fluoro-l-phenylalanine fdopa positron emission tomography pet
feasibility and potential aids of intra-operative endo-vaginal ultrasound when performing rectal shaving for endometriosis

Conditions: Endometriosis

Summary: the protocol of this study consists in the inclusion of patients with endometriosic rectal involvement with a scheduled intervention. an endovaginal ultrasound will be performed in the operating room by the radiology team to confirm the operative indication of rectal shaving then in a second step a second ultrasound in the operating room will confirm the complete excision of the lesion or the case will allow to perform a more complete gesture (discoid or segmental resection) if the shaving is not sufficient with ultrasound and / or macroscopically


Eligibility criteria:
inclusion criteria: * age \>18 years * deep pelvic endometriosis with symptomatic rectal involvement * with surgical indication of rectal shaving validated in "rcp" or during the pre-operative consultation by the surgeon exclusion criteria: * history of inflammatory digestive pathology

Keywords: deep pelvic endometriosis rectal shaving segmental digestive resection endovaginal ultrasound
obesity and intracytoplasmic sperm injection cycle outcome

Conditions: Infertility

Summary: obesity has been associated with menstrual irregularities, chronic an-ovulation, infertility, and poor outcomes in women undergoing in vitro fertilization. there is strong evidence that obesity is associated with a higher n vitro fertilization cycle cancellation rate (despite administration of higher doses of exogenous gonadotrophins), a lower mature oocyte yield and lower number of cryopreservation cycles. furthermore, obese women have been shown to have impaired response to ovarian stimulation and significantly lower live births after in vitro fertilization. indeed, obesity affects many ovarian intra-follicular steroidogenic, metabolic and inflammatory pathways.this is particularly evident in women with abdominal (central obesity). waist circumference measurement is used to identify individuals with abdominal obesity but it cannot differentiate between intra-abdominal fat and subcutaneous abdominal fat accumulation. the reliable measurement of visceral fat and subcutaneous fat is not only important as a tool to predict cardiovascular and metabolic disease risk, but it is also essential to evaluate the effect of these fat compartments on female reproductive function. intra-abdominal fat accumulation is related to insulin resistance in women with polycystic ovary syndrome and in these women the resulting hyperinsulinemia contributes to an-ovulation. obese anovulatory women with polycystic ovary syndrome who resume ovulation during a 6-month lifestyle program lose more visceral fat with no difference in the change of subcutaneous fat compared to the women who did not resume ovulation. another recent study that enrolled 140 non-polycystic ovary syndrome in vitro fertilization women demonstrated that women with increased waist circumference and higher follicular fluid leptin have less oocytes fertilized and failed in vitro fertilization outcomes. increased intra-abdominal fat during early pregnancy is associated with insulin resistance and increased diastolic blood pressure and it can predict glucose intolerance in later pregnancy.


Eligibility criteria:
inclusion criteria: * age of women 18 - 35 yrs old. * women with body mass index i 18 - 35 kg/m2. * infertile women with an indication for in vitro fertilization * anticipated normal responders. * normal uterine cavity by trans-vaginal ultrasound. exclusion criteria: * poly cystic ovarian syndrome * diabetic patients. * known poor ovarian response * patients with abnormal uterine cavity. * refusal to participate in the study.